Gsa Capital Partners LLP Protalix Bio Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.35 Billion
- Q4 2024
A detailed history of Gsa Capital Partners LLP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 305,749 shares of PLX stock, worth $709,337. This represents 0.04% of its overall portfolio holdings.
Number of Shares
305,749
Previous 435,213
29.75%
Holding current value
$709,337
Previous $444,000
29.5%
% of portfolio
0.04%
Previous 0.03%
Shares
11 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
4.58MCall Options Held
40.9KPut Options Held
5.3K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.12MShares$2.59 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL732KShares$1.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny388KShares$899,9760.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$772,9560.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$626,4000.01% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $115M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...